U.S. Markets close in 1 hr 30 mins

Seattle Genetics, Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
46.70+0.33 (+0.71%)
As of 2:30PM EDT. Market open.
People also watch
IMGNBMRNINCYALNYCLDX

Seattle Genetics, Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425-527-4000
http://www.seattlegenetics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees890

Key Executives

NameTitlePayExercisedAge
Dr. Clay B. Siegall Ph.D.Co-Founder, Pres, CEO & Chairman1.86M8.7M56
Mr. Todd E. SimpsonChief Financial Officer757.28kN/A56
Mr. Eric L. Dobmeier J.D.Chief Operating Officer727.84k1.63M48
Dr. Vaughn B. Himes Ph.D.Chief Technology Officer700.44k2.41M56
Dr. Jonathan G. Drachman M.D.Chief Medical Officer and Exec. VP of R&D817.17k720.86k55
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Corporate Governance

Seattle Genetics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.